Baird raised the firm’s price target on Taysha Gene Therapies to $8 from $6 and keeps an Outperform rating on the shares. The firm is postive on early clinical data from Rett program.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on TSHA:
- Why Taysha Gene Therapies (NASDAQ:TSHA) Doubled Its Value Today
- Cantor ups Taysha target to $7 from $2 after ‘robust’ Rett data
- Taysha Gene Therapies price target raised to $7 from $2 at Cantor Fitzgerald
- Taysha Gene Therapies expects cash to fund operations into 3Q25
- Taysha Gene Therapies reports Q2 EPS (38c), consensus (31c)